Biotinoyl Tripeptide

Biotinoyl Tripeptide-1, biotinyl-GHK

Biotinoyl Tripeptide (Biotinoyl Tripeptide-1, biotinyl-GHK) is a healing & recovery research compound. The GHK tripeptide with a biotin molecule attached. GHK on its own is the copper-binding signal peptide already in this Vault; conjugating biotin is a delivery and stability decision rather than a new mechanism — the lipophilic biotin tail is intended to help the peptide associate with and persist in the follicle. The proposed action at the follicle is reinforcement of the dermal-epidermal junction: stimulating laminin-5 and collagen IV at the hair bulb so the shaft is anchored more firmly and resists shedding.

How Biotinoyl Tripeptide works

The GHK tripeptide with a biotin molecule attached. GHK on its own is the copper-binding signal peptide already in this Vault; conjugating biotin is a delivery and stability decision rather than a new mechanism — the lipophilic biotin tail is intended to help the peptide associate with and persist in the follicle. The proposed action at the follicle is reinforcement of the dermal-epidermal junction: stimulating laminin-5 and collagen IV at the hair bulb so the shaft is anchored more firmly and resists shedding.

Proposed benefits

Hair and scalp support — a biotinylated tripeptide used topically for follicle anchoring, breakage resistance and the appearance of density. The defensible route in is the sodium-dependent multivitamin transporter human keratinocytes express, which carries the biotin end (cosmetic, not systemic).

Where to get Biotinoyl Tripeptide

The evidence for Biotinoyl Tripeptide

Graded by what exists behind each claim.

✅ Clinically validated

• No independent controlled human trials of this molecule on its own. The supporting studies come from the cosmetic-ingredient suppliers who sell the raw material, and almost always test it inside a multi-ingredient complex — which cannot tell you what this peptide contributes by itself.

📊 Correlative data

• A long-standing ingredient in hair and lash formulations, usually alongside other actives. Reported experience is modest and slow, and very difficult to separate from the rest of the formula or from the regression to the mean that follows starting any hair routine during a shedding phase.

🧪 Theoretical / extrapolated

• The GHK tripeptide with biotin conjugated to it. GHK is already a well-characterized copper-binding signal peptide; attaching a lipophilic biotin tail is a delivery and stability decision, not a new mechanism — it is meant to help the peptide associate with and persist in the follicle.
• The proposed action is reinforcement of the dermal-epidermal junction — stimulating laminin-5 and collagen IV at the hair bulb so the shaft anchors more firmly and resists shedding. Plausible, and largely untested independently.
• If the goal is the scalp, the better-evidenced options are on other cards: GHK-Cu and AHK-Cu topically, and — with real attention to their systemic effects — Minoxidil and RU-58841.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Biotinoyl Tripeptide actually does

The peptide is Gly-His-Lys with a biotin residue attached through an amide bond. Computed: free GHK is 340.38 Da; biotin minus water contributes 226.29 Da; the conjugate is 566.67 Da, of which 39.9% by mass is biotin. Acylating the N-terminus takes the net charge from +1.92 to about +0.92 at skin-surface pH and from +1.05 to +0.11 at blood pH, with the isoelectric point falling from 9.70 to 8.65.

The first correction, and it undoes the usual explanation. This conjugate is routinely described as the peptide given a lipophilic tail, by analogy with the palmitoylated peptides in this Vault. Biotin is not a lipid. It is vitamin B7: a water-soluble molecule with a fused bicyclic ureido-thiophane ring and a five-carbon valeric acid arm, and it is soluble in water in a way a 16-carbon fatty acid is not. Whatever attaching it achieves, it is not the lipid-partitioning trick that the palmitoyl peptides use, and every description that borrows that explanation is borrowing the wrong one.

So what is it for? There is a real answer, and nobody in this market gives it. Human keratinocytes carry a working sodium-dependent multivitamin transporter for biotin. It has been characterized directly in human keratinocytes: a Michaelis constant of 22.7 ± 1.0 µM, a maximal velocity of 163.6 ± 3.5 pmol per 5 min per mg protein, and a separate high-affinity component with a transport constant of 2.6 ± 0.1 nM; uptake is competitively inhibited by lipoic acid, pantothenic acid and desthiobiotin Grafe 2003. The same transporter is an established target for delivering drugs into cells as biotin conjugates — a 635-residue, twelve-transmembrane carrier used deliberately in prodrug design Vadlapudi 2012. That gives biotinylation a coherent purpose that has nothing to do with greasiness: it is a plausible transporter-targeting strategy, aimed at a carrier the target cell actually expresses. This is extrapolation and is labeled as such — no one has tested whether this particular conjugate is a substrate — but it is a far better account of the design than the lipophilicity story, and it is testable.

The second correction, and it concerns copper. GHK is a copper carrier, and the metal is held by three nitrogens and an oxygen with the free N-terminal amine as the first donor Alshammari 2020. If the biotin is attached there — which is what an N-acyl name implies — the copper site is destroyed. But the one biotinylated GHK that has been made and characterized in the peer-reviewed literature still coordinates copper(II), confirmed spectroscopically and by mass spectrometry Tosto 2023. Both statements can only be true if that conjugate carries its biotin somewhere other than the N-terminal nitrogen — the lysine side-chain amine being the obvious alternative. The two regiochemistries have identical molecular formulas and identical masses, so a certificate of analysis reporting 566.7 Da is equally consistent with a molecule that binds copper and one that cannot. No supplier publishes which nitrogen carries the biotin, and it decides whether this is a copper peptide or a copper-blind one.

And the published conjugate is not about hair. The biotinylated GHK in the literature was made to chase amyloid: it was assessed for antioxidant activity by copper-induced ascorbate oxidation, for antiglycation by mass spectrometry, for streptavidin binding, and for anti-aggregation against amyloid-beta, in the context of neurodegenerative disease Tosto 2023. Not a follicle in sight.

Cell, rodent, human — and where it stops

Cells: the peptide has a literature, the conjugate has one paper, and neither is about a hair follicle. Free GHK modulates a wide set of pathways in skin regeneration Pickart 2015 and suppresses TNF-alpha-driven interleukin-6 in normal human dermal fibroblasts Gruchlik 2012. The biotinylated version has exactly one peer-reviewed characterization, and its read-outs are copper-ascorbate redox chemistry, glycation and amyloid-beta aggregation Tosto 2023. There is no published experiment putting this conjugate on a keratinocyte, a dermal papilla cell, or a hair follicle.

The mechanism the card claims, and where it comes from. The proposed action is reinforcement of the dermal-epidermal junction — laminin-5 and collagen IV at the hair bulb, anchoring the shaft against shedding. That is a specific, checkable claim, and searching the indexed literature for it against this molecule returns nothing. It is supplier material. Saying so is not a dismissal of the idea; the junction proteins are real and the anchoring logic is sound. It means the claim has never been through a review process.

Rodents: none. No animal study of biotinoyl tripeptide-1 has been published.

Humans: none of this molecule, and the nearest study is worth reading precisely because it is somebody else’s. The one indexed clinical study of a cosmetic peptide-plus-botanical for hair loss enrolled 30 volunteers with receding hair for 4 months of daily topical application and reported anagen hair +13%, telogen hair −29% and an anagen-to-telogen ratio +46%, attributed to 5-alpha-reductase inhibition, reduced inflammation and stimulated extracellular-matrix synthesis Loing 2013. Read the design: manufacturer-run, no control arm described, 30 people, self-selected. And read the ingredients: it tested a red clover extract with a different biomimetic peptide, not this conjugate. That is the ceiling of the evidence in this category — and it belongs to another molecule. The recent overview of short peptides for hair loss surveys the whole field without a controlled human trial for any of them Fan 2026.

The obstacle, and it is not the one people expect. At 566.67 Da the conjugate is over the 500 Da rule of thumb for stratum corneum Bos 2000, and peptide permeability is the field’s standing gap Mortazavi 2022. But the biotin arm changes the question. If the multivitamin transporter carries it, size is not the governing constraint, because a carrier-mediated route does not care about the 500 Da rule. So the arithmetic that matters is a saturation calculation. A milliliter of a 0.001% scalp serum contains 10 µg of conjugate, about 17.6 nanomoles. Distributed through 100 cm² of scalp at 3 mm depth — roughly 30 mL of tissue — complete delivery would give about 0.59 µM. Against the 22.7 µM Michaelis constant of the low-affinity component that is only 2.6% of half-saturation; but against the 2.6 nM high-affinity component in the same keratinocyte study Grafe 2003, even a 1% delivery fraction would saturate it several-fold. The transporter hypothesis survives the arithmetic, and it survives it specifically at the high-affinity site. That is the single most useful sentence anybody can currently write about this ingredient.

Biotinoyl Tripeptide pharmacokinetics — how much of it actually gets in

What degrades it. Scalp skin is proteolytic. The biotinoyl amide caps the peptide’s N-terminus and takes it out of reach of aminopeptidases, in the same way an acyl group does for the palmitoylated members of this family; the His-Lys bond and the free C-terminus stay exposed. No degradation rate has been measured for this conjugate in skin, in serum, or anywhere else.

The barrier, and the alternative to it. 566.67 Da against a 500 Da threshold Bos 2000. The passive route is therefore unpromising and the two live alternatives are the follicular opening, which for a scalp product is the intended target anyway, and the multivitamin transporter that human keratinocytes actually express Grafe 2003 Vadlapudi 2012. Neither has been measured for this molecule.

The quantities, computed. Finished formulas in this Vault are listed at 0.0001–0.001%. A gram of product at that range contains 1 to 10 µg of conjugate. Because biotin is 39.9% of the conjugate by mass, complete hydrolysis of an entire application would liberate 0.4 to 4 µg of biotin equivalent. Hold that number; the safety section needs it.

The competitive-inhibition problem, which is a pharmacokinetic issue and not a biological one. Uptake by that keratinocyte transporter is competitively inhibited by pantothenic acid with an inhibition constant of 1.2 µM, and by lipoic acid at 4.6 µM oxidized and 11.4 µM reduced Grafe 2003. Panthenol is one of the most common ingredients in scalp and hair products and is converted to pantothenate in tissue. A 1% panthenol serum applied at 1 mL over 100 cm² puts about 10 mg — roughly 49 micromoles — onto the same skin; even one per cent of that reaching the same 30 mL of tissue gives about 16 µM, more than ten times the inhibition constant. If this ingredient works through the multivitamin transporter, then formulating it beside panthenol should block it, and the two are routinely sold in the same bottle. That is an extrapolation from a measured inhibition constant, it is labeled as one, and it is trivially testable.

Systemic exposure. Micrograms applied to intact scalp, of a conjugate that is over the passive size limit, gives no meaningful circulating concentration by any route that has been measured.

What would have to be true, and how you would know it was not

What to watch. A fixed-frame scalp photograph — same parting, same lighting, same camera height, hair damp and combed identically — at week 0, week 16 and week 24, plus a shed count collected on a fixed wash day. If the claimed mechanism is anchoring at the dermal-epidermal junction rather than growth stimulation, then shed count is the primary endpoint and density is a secondary consequence of it.

How long before it means anything. Sixteen to twenty-four weeks. Anagen-to-telogen ratios in the nearest published study moved over four months Loing 2013, and a hair released from telogen still needs months of growth before a camera can see it.

What will fool you. The formula. This ingredient is sold inside multi-active complexes, and the accompanying botanical, caffeine or vasodilator is more likely than the peptide to be doing anything. The second trap is the shed cycle: starting any scalp routine during a telogen effluvium guarantees improvement on the effluvium’s own schedule.

Prediction 1, the transporter test, and it is falsifiable in both directions. Formulate the conjugate with and without 1% panthenol. If the multivitamin transporter is the delivery route, the panthenol arm should be measurably worse, because pantothenate competitively inhibits that carrier at 1.2 µM and a panthenol serum delivers far more than that Grafe 2003. If the two arms are identical, the transporter hypothesis is dead and the ingredient is getting in passively or not at all. Either result is new.

Prediction 2, and it cuts against the compound. Serum copper and ceruloplasmin will not move. Whether or not the conjugate binds copper — and the published biotinylated GHK does Tosto 2023 — the mass involved is micrograms of peptide, not of metal, and a topical at these concentrations cannot shift a systemic copper pool supplied by milligrams of dietary copper daily. Anybody buying this as a copper therapy is buying a rounding error.

Prediction 3, the one that has a real clinical consequence and is not on any product page. Because biotin is nearly 40% of this molecule by mass, the honest question is whether it can disturb streptavidin-based laboratory tests, which is a documented, dose-dependent phenomenon Li 2020. The direction is specific: sandwich immunoassays read falsely low — high-sensitivity troponin T, thyroid-stimulating hormone and follicle-stimulating hormone — while competitive assays read falsely high, notably triiodothyronine and vitamin D Li 2018. The prediction here is that a topical at 0.0001 to 0.001% produces no such interference, because the entire biotin content of an application is 0.4 to 4 micrograms against oral supplements that cause it at milligram doses — a gap of three to four orders of magnitude. If someone on a topical scalp peptide produces an odd TSH, the biotin capsule in their cupboard is the culprit, not the serum, and this is the arithmetic that separates them.

What nobody has tested yet

1. Nobody has published which nitrogen carries the biotin. The N-terminal amine and the lysine side chain give conjugates of identical mass and completely different copper chemistry Alshammari 2020 Tosto 2023. Nuclear magnetic resonance on commercial material would settle it in a morning, and it decides whether this ingredient is a copper carrier or a molecule that merely looks like one.

2. Nobody has asked whether the multivitamin transporter accepts it. Sodium-dependent, saturable uptake of the labeled conjugate into cultured human keratinocytes, with free biotin as the competitor, is a standard assay and the parent transporter is fully characterized in exactly that cell type Grafe 2003. This is the single most informative unrun experiment on this page: it would either give the ingredient a delivery mechanism nothing else in this Vault has Vadlapudi 2012, or remove the only good reason for the biotin to be there.

3. The panthenol interference has never been tested. A measured inhibition constant of 1.2 µM for pantothenate against that carrier Grafe 2003, and an industry that routinely co-formulates panthenol with peptides, is a collision nobody has checked. One uptake experiment with and without pantothenate would answer it, and the answer would apply to every biotinylated cosmetic ingredient at once.

4. There is no laminin-5 or collagen IV experiment. The mechanism this ingredient is sold on is a dermal-epidermal junction claim, and no published study has measured either protein in response to it. Human skin explants or an organotypic culture, immunostained for both, is the direct test and it has never been reported.

5. Nobody has compared the conjugate with the free peptide on hair. Free GHK has a substantial skin literature Pickart 2015 Gruchlik 2012; the biotinylated form has one paper about amyloid Tosto 2023. Putting both on human follicles at equal molarity would show whether biotinylation adds delivery, subtracts activity, or does nothing at all — and would be the first experiment ever run on this ingredient for the purpose it is sold for Fan 2026.

Biotinoyl Tripeptide — its own safety story, not its class's

The class block above is written for injectable repair peptides. Three things on this card are its own, and the first one is the reason the page needed writing.

The laboratory-test question, answered with arithmetic instead of a warning. Biotin interferes with immunoassays that use the streptavidin-biotin binding system, the interference is dose-dependent, and it is a recognized clinical problem Li 2020. The published biotinylated GHK does bind streptavidin Tosto 2023, so the intact conjugate is chemically capable of the same interference — which nobody has considered. Then the quantities settle it: an application of a formula at 0.0001 to 0.001% contains 1 to 10 µg of conjugate, of which biotin is 39.9% by mass, so 0.4 to 4 µg of biotin equivalent, against the milligram-dose oral supplements that produce the effect. That is a margin of three to four orders of magnitude. The conclusion is reassurance, and it is reassurance you can check — which is worth more than the same conclusion asserted. The direction of the error is worth knowing anyway, because people on this ingredient are often also taking oral biotin: sandwich assays fall (troponin T, thyroid-stimulating hormone, follicle-stimulating hormone) and competitive assays rise (triiodothyronine, vitamin D) Li 2018. If a thyroid panel looks strange, ask about the capsules, not the serum.

Vitamin C, and why the answer depends on a structure nobody has published. If the biotin sits on the lysine side chain, the copper site is intact and the conjugate is a copper carrier — and ascorbate plus copper is a redox pair used as an assay in this very peptide family Tosto 2023. If the biotin sits on the N-terminus, the site is gone and there is no interaction to manage Alshammari 2020. Same ingredient name, same mass on the certificate, two different answers about whether to layer it with an L-ascorbic acid serum. Until a supplier publishes the structure, separating the two products by time of day is the cheap way to be right either way.

The formulation interaction that is specific to this molecule. Nothing else in this Vault has a plausible dependence on a vitamin transporter, and nothing else can therefore be blocked by a vitamin. Pantothenate inhibits that carrier at 1.2 µM and lipoic acid at 4.6 µM Grafe 2003; panthenol and lipoic acid are both common in scalp products. This is not a safety risk — it is a wasted-money risk, and it is the kind of interaction that only exists if the mechanism is real, which makes checking it doubly worthwhile.

What the absence of adverse events means here. There has never been a controlled trial of this ingredient on a human scalp, so no arm has existed in which an adverse event could be recorded Fan 2026. Wide cosmetic use without a signal is genuine reassurance about irritation at these concentrations, and it is not evidence of anything else. The real cost of this compound is the months a person spends on it while a treatable pattern hair loss progresses.

Sources read for this page

• Tosto R, Bellia F, Pandini G, Naletova I, Attanasio F, Zimbone S, Grasso G. New Biotinylated GHK and Related Copper(II) Complex: Antioxidant and Antiglycant Properties In Vitro against Neurodegenerative Disorders. Molecules 2023 · PMID 37764500
• Alshammari N, Platts JA. Theoretical study of copper binding to GHK peptide. Comput Biol Chem 2020 · PMID 32371360
• Grafe F, Wohlrab W, Neubert RH, Brandsch M. Transport of biotin in human keratinocytes. J Invest Dermatol 2003 · PMID 12603856
• Vadlapudi AD, Vadlapatla RK, Mitra AK. Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. Curr Drug Targets 2012 · PMID 22420308
• Loing E, Lachance R, Ollier V, Hocquaux M. A new strategy to modulate alopecia using a combination of two specific and unique ingredients. J Cosmet Sci 2013 · PMID 23449130
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015 · PMID 26236730
• Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm 2012 · PMID 23285694
• Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 · PMID 10839713
• Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC Guidance Document on Biotin Interference in Laboratory Tests. J Appl Lab Med 2020 · PMID 32445355
• Li J, Wagar EA, Meng QH. Comprehensive assessment of biotin interference in immunoassays. Clin Chim Acta 2018 · PMID 30296442
• Fan C, Zhang Y, Wang J. Overview of Short Peptides for Hair Loss. Biomedicines 2026 · PMID 42072405
• Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci 2022 · PMID 35302659

Biotinoyl Tripeptide — safety, predicted from mechanism

Biotinoyl Tripeptide — interference & stacking

Bloodwork to run alongside Biotinoyl Tripeptide

Baseline first, then again at 8–12 weeks.

The Thyroid — First Look panel covers these in one order — 2 markers, $19.80 with the discount applied.

Check results you already have → · All 103 markers A–Z

Biotinoyl Tripeptide — frequently asked questions

What Biotinoyl Tripeptide is used for

Biotinoyl Tripeptide appears under 1 goal in the goal router.

Related Healing & Recovery compounds

← Explore the full Protocol Vault

↑ Back to on this page